Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty
- Registration Number
- NCT06244498
- Lead Sponsor
- Piotr Biega
- Brief Summary
This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.
- Detailed Description
Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
- Patological fracture
- Arthroplasty using a modular prosthesis.
Exclusion Criteria
- threatened fracture
- intraoperative blood transfusion
- fracture fixation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description TXA Tranexamic acid injection Tranexamic acid was administered to the participants at a dose of 1.0 g during the induction of anaesthesia and immediately after the operation.
- Primary Outcome Measures
Name Time Method Number of participants who require a blood transfusion. During Hospitalization (up to day 10) Need of blood transfusion
- Secondary Outcome Measures
Name Time Method Estimeted blood lost after surgery. During Hospitalization (up to day 3) Gross total blood loss was estimated utilizing the formula PBV × (Hctpre- Hctpost)/Hcta
Number of participants with embolic complication. During Hospitalization (up to day 10) Yes or No
Trial Locations
- Locations (1)
SzSPOO Brzozów
🇵🇱Brzozów, Podkarpackie, Poland
SzSPOO Brzozów🇵🇱Brzozów, Podkarpackie, Poland